Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Retained Earnings (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Retained Earnings data on record, last reported at -$221.6 million in Q3 2025.

  • For Q3 2025, Retained Earnings fell 46.26% year-over-year to -$221.6 million; the TTM value through Sep 2025 reached -$221.6 million, down 46.26%, while the annual FY2024 figure was -$172.4 million, 31.03% down from the prior year.
  • Retained Earnings reached -$221.6 million in Q3 2025 per MBRX's latest filing, down from -$196.2 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$61.4 million in Q1 2021 and bottomed at -$221.6 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$121.5 million, with a median of -$115.7 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: crashed 50.51% in 2021, then decreased 21.78% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$72.8 million in 2021, then plummeted by 39.86% to -$101.8 million in 2022, then fell by 29.23% to -$131.6 million in 2023, then plummeted by 31.03% to -$172.4 million in 2024, then decreased by 28.48% to -$221.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$221.6 million in Q3 2025, -$196.2 million in Q2 2025, and -$178.3 million in Q1 2025.